MedTrace Logo

A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma

NCT00426764 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 131

Last updated 2020-02-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the activity of romidepsin in patients with progressive or relapsed peripheral T-cell lymphoma (PTCL) who have already been treated with systemic therapy.

Conditions

  • Peripheral T-cell Lymphoma

Interventions

DRUG

Romidepsin

Romidepsin intravenously (through a vein) over 4 hours on Days 1, 8 and 15 of each 28-day cycle.

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Myron Czuczman, MD · Celgene

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-19
Primary Completion
2010-11-11
Completion
2018-05-17

Countries

  • United States
  • Australia
  • Czechia
  • France
  • Germany
  • Poland
  • Spain
  • Sweden
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00426764 on ClinicalTrials.gov